Clinical trials: completed, sponsored by Janssen Research & Development, LLC
Healthy
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly Participants
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of JNJ-42165279 in healthy, young and elderly, male and female participants after repeated oral dose administration.
- Trial name
- NCT01964651
- Testing
- JNJ-42165279 50 mg, JNJ-42165279 100 mg, JNJ-42165279 30 mg
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy Volunteers
A Study to Assess the Relative Bioavailability of 4 New Abiraterone Acetate Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions in Healthy Male Participants
The purpose of this study is to evaluate the relative bioavailability of 4 new formulations of abiraterone acetate compared to the current commercial formulation.
- Trial name
- NCT01897389
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Neoplasm Metastases
A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies
The purpose of this study is to evaluate the potential effects of rifampin on blood levels of trabectedin after administration to patients with advanced malignancies.
- Trial name
- NCT01273480
- Testing
- Sequence 1, Sequence 2
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Janssen Research & Development, LLC
Bioequivalence
Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants
The purpose of this study is to evaluate the bioequivalence of metformin component of the canagliflozin and metformin immediate release (IR) fixed dose combination (FDC) tablet compared with the metformin IR tablet…
- Trial name
- NCT02221180
- Testing
- Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC], Canagliflozin, Metformin
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants
The purpose of this study is to evaluate the effects of JNJ-54861911 on the QT/QTc intervals in healthy participants, when administered at therapeutic (50 milligram [mg] once-daily) and supratherapeutic (150 mg once-daily) doses…
- Trial name
- NCT02152332
- Testing
- JNJ-54861911-Therapeutic Dose, JNJ-54861911 - Supratherapeutic Dose, Moxifloxacin
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants
The purpose of this study to evaluate the bioequivalence (is the amount same in both the pills) of metformin component of the canagliflozin and metformin immediate release (IR) fixed dose combination (FDC) tablet compared with…
- Trial name
- NCT02220218
- Testing
- Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC), Canagliflozin, Metformin IR
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients
The purpose of this study is to evaluate safety and effectiveness of CNTO 328 (siltuximab) when it is administered together with velcade-melphalan-prednisone (VMP) in comparison with VMP alone in participants with multiple…
- Trial name
- NCT00911859
- Testing
- Siltuximab11 mg/kg, Siltuximab 8.3 mg/kg or 11 mg/kg, Velcade (bortezomib)
- Where
- 37 sites in United States, Australia and 9 more
- Volunteers
- 118 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo
The purpose of this study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of JNJ-54861911 which is currently being developed for the treatment of Alzheimer's Disease.
- Trial name
- NCT01827982
- Testing
- JNJ-54861911 1mg, JNJ-54861911 3 mg, JNJ-54861911 9 mg
- Where
- Belgium
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy Participants
A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants
The purpose of this study is to investigate the absorption, the metabolic pathways and the excretion of ibrutinib in healthy male adult participants after administration of a single oral dose of 50 mg to 140 mg (5 mg/mL solution)…
- Trial name
- NCT01674322
- Testing
- Ibrutinib
- Where
- Belgium
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in older patients (55 to 80 years of age) with type 2 diabetes mellitus (T2DM) with inadequate control…
- Trial name
- NCT01106651
- Testing
- Canagliflozin 100 mg, Canagliflozin 300 mg, Antihyperglycemic agent(s)
- Where
- 86 sites in United States, Australia and 15 more
- Volunteers
- 716 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
An Exploratory Genetic Study in Participants With Psoriasis
The purpose of this study is to evaluate the association between genetic factors and response to treatment (guselkumab, ustekinumab, adalimumab, or etanercept) and psoriasis (scaly skin rash).
- Trial name
- NCT02155192
- Testing
- No Intervention
- Where
- 19 sites in United States, Canada
- Volunteers
- 712 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study to Evaluate the Effect of Intranasal Esketamine on Cognitive Functioning in Healthy Subjects
The purpose of this study is to assess the cognitive effects associated with administration of intranasal esketamine 84 mg.
- Trial name
- NCT02094378
- Testing
- Esketamine
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers
The purpose of this study is to evaluate the potential efficacy of JNJ-42165279 in treating anxiety disorders through evaluation of brain activation patterns using imaging technology in healthy volunteers.
- Trial name
- NCT01826786
- Testing
- JNJ-42165279 (100 mg)
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants
The purpose of this study is to assess the effects of strong cytochrome P450 (CYP) 3A4 inhibitors (Itraconazole and Clarithromycin), on pharmacokinetics (PK) (study of the way a drug enters and leaves the blood and tissues over…
- Trial name
- NCT02197884
- Testing
- JNJ-54861911, 25 mg, Itraconazole 200 mg, Clarithromycin 500 mg
- Where
- Belgium
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male Participants
The purpose of this study is to determine pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) and the relative-bioavailability (the extent to which a drug or other substance becomes…
- Trial name
- NCT02260700
- Testing
- JNJ-54861911 (Treatment A), JNJ-54861911 (Treatment B), JNJ-54861911 (Treatment C)
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy, Renal Insufficiency
A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function
The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamics of rivaroxaban when administered with erythromycin to study participants with mild or moderate renal impairment compared to the pharmacokinetics…
- Trial name
- NCT01309438
- Testing
- Rivaroxaban (normal renal function), Rivaroxaban (mild and moderate renal impairment), Erythromycin (normal renal function)
- Where
- 4 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Ejaculation
A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin
The purpose of this study is to assess the pharmacodynamics (the actions or effects a drug has on the body), pharmacokinetics (blood levels), safety, and tolerability of dapoxetine 60 mg when concomitantly administered in…
- Trial name
- NCT01366664
- Testing
- Treatment sequence 2, Treatment sequence 1
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Janssen Research & Development, LLC
Hepatic Impairment
A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment
The purpose of this study is to evaluate the pharmacokinetics (how the drug concentrations change over time) of PCI 32765 in participants with mild, moderate, or severe hepatic impairment.
- Trial name
- NCT01767948
- Testing
- PCI-32765
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Bioequivalence Study of Norgestimate /Ethinyl Estradiol (NGM/EE) Tablets Manufactured at 2 Different Facilities
The purpose of this study is to establish the bioequivalence of the hormones norgestimate, norelgestromin, and ethinyl estradiol in norgestimate/ethinyl estradiol (NGM/EE) tablets, formulated by wet process compared with the same…
- Trial name
- NCT02127593
- Testing
- Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Wet Process), Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Dry Process)
- Where
- Netherlands
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants
The purpose of this study is to find out if different doses of CNTO 3157 are well tolerated in both Japanese and Caucasian men as well as to understand how the body absorbs and removes the study drug after being injected or…
- Trial name
- NCT02008279
- Testing
- 100 mg CNTO 3157, 300 mg CNTO 3157, 600 mg CNTO 3157
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC